Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions

• Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

  2020 Blood article Medicine Multiple Myeloma Research and Treatments Open access

  703

  citations
• Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

  2020 The Lancet Haematology article Medicine Multiple Myeloma Research and Treatments Open access cited by 2 patents

  384

  citations
• Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

  2021 The Lancet Oncology article Medicine Multiple Myeloma Research and Treatments Open access

  376

  citations
• Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

  2021 The Lancet Oncology article Medicine Multiple Myeloma Research and Treatments Open access

  182

  citations
• CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide

  2020 Nature Communications article Medicine CAR-T cell therapy research Open access cited by 4 patents

  79

  citations
• Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial

  2020 The Lancet Haematology article Medicine Multiple Myeloma Research and Treatments Open access cited by 1 patent

  36

  citations
• Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

  2021 Blood conference-abstract Medicine Multiple Myeloma Research and Treatments

  33

  citations
• Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT

  2020 Bone Marrow Transplantation article Medicine Multiple Myeloma Research and Treatments Open access

  14

  citations
• Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors

  2020 Annals of Hematology article Medicine Multiple Myeloma Research and Treatments Open access

  10

  citations
• Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

  2021 Transplantation and Cellular Therapy article Medicine Hematopoietic Stem Cell Transplantation Open access

  10

  citations
• Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

  2021 Bone Marrow Transplantation article Medicine Hematopoietic Stem Cell Transplantation Open access

  4

  citations

11 results